Plasma cyclophilin a is a novel biomarker for coronary artery disease

Circulation Journal

Volumn 77, Issue 2, 2013, Pages 447-455

  Satoh, Kimio ^a   Fukumoto, Yoshihiro ^a   Sugimura, Koichiro ^a   Miura, Yutaka ^a   Aoki, Tatsuo ^a   Nochioka, Kotaro ^a   Tatebe, Shunsuke ^a   Miyamichi Yamamoto, Saori ^a   Shimizu, Toru ^a   Osaki, Shizuka ^a   Takagi, Yusuke ^a   Tsuburaya, Ryuji ^a   Ito, Yoshitaka ^a   Matsumoto, Yasuharu ^a   Nakayama, Masaharu ^a   Takeda, Morihiko ^a   Takahashi, Jun ^a   Ito, Kenta ^a   Yasuda, Satoshi ^a   Shimokawa, Hiroaki ^a  

^a TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Biomarker; Coronary artery disease; Oxidative stress

Indexed keywords

BIOLOGICAL MARKER; CYCLOPHILIN A;

ADULT; AGED; ANGIOCARDIOGRAPHY; ARTICLE; ATHEROSCLEROTIC PLAQUE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORONARY ARTERY OBSTRUCTION; DISEASE SEVERITY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOASSAY; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; OXIDATIVE STRESS; PROSPECTIVE STUDY; PROTEIN EXPRESSION;

AGED; BIOLOGICAL MARKERS; COMORBIDITY; CORONARY ANGIOGRAPHY; CORONARY ARTERY DISEASE; CORONARY STENOSIS; CYCLOPHILIN A; FEMALE; HUMANS; MALE; MIDDLE AGED; ODDS RATIO; PROGNOSIS; PROSPECTIVE STUDIES; RISK FACTORS; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX;

EID: 84873823252     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-12-0805     Document Type: Article

References (36)

1. Berk BC. Atheroprotective signaling mechanisms activated by steady laminar flow in endothelial cells. Circulation 2008; 117: 1082-1089.
2. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005; 352: 1685-1695.
3. Dzau VJ, Antman EM, Black HR, Hayes DL, Manson JE, Plutzky J, et al. The cardiovascular disease continuum validated: Clinical evidence of improved patient outcomes. Part I: Pathophysiology and clinical trial evidence (risk factors through stable coronary artery disease). Circulation 2006; 114: 2850-2870.
4. Jin ZG, Melaragno MG, Liao DF, Yan C, Haendeler J, Suh YA, et al. Cyclophilin A is a secreted growth factor induced by oxidative stress. Circ Res 2000; 87: 789-796.
5. Liao DF, Jin ZG, Baas AS, Daum G, Gygi SP, Aebersold R, et al. Purification and identification of secreted oxidative stress-induced factors from vascular smooth muscle cells. J Biol Chem 2000; 275: 189-196.
6. Jin ZG, Lungu AO, Xie L, Wang M, Wong C, Berk BC. Cyclophilin A is a proinflammatory cytokine that activates endothelial cells. Arterioscler Thromb Vasc Biol 2004; 24: 1186-1191.
7. Suzuki J, Jin ZG, Meoli DF, Matoba T, Berk BC. Cyclophilin A is secreted by a vesicular pathway in vascular smooth muscle cells. Circ Res 2006; 98: 811-817.
8. Satoh K, Matoba T, Suzuki J, O'Dell MR, Nigro P, Cui Z, et al. Cyclophilin A mediates vascular remodeling by promoting inflammation and vascular smooth muscle cell proliferation. Circulation 2008; 117: 3088-3098.
9. Handschumacher RE, Harding MW, Rice J, Drugge RJ, Speicher DW. Cyclophilin: A specific cytosolic binding protein for cyclosporin A. Science 1984; 226: 544-547.
10. Pan H, Luo C, Li R, Qiao A, Zhang L, Mines M, et al. Cyclophilin A is required for CXCR4-mediated nuclear export of heterogeneous nuclear ribonucleoprotein A2, activation and nuclear translocation of ERK1/2, and chemotactic cell migration. J Biol Chem 2008; 283: 623-637.
11. Zhu C, Wang X, Deinum J, Huang Z, Gao J, Modjtahedi N, et al. Cyclophilin A participates in the nuclear translocation of apoptosisinducing factor in neurons after cerebral hypoxia-ischemia. J Exp Med 2007; 204: 1741-1748.
12. Arora K, Gwinn WM, Bower MA, Watson A, Okwumabua I, MacDonald HR, et al. Extracellular cyclophilins contribute to the regulation of inflammatory responses. J Immunol 2005; 175: 517-522.
13. Damsker JM, Bukrinsky MI, Constant SL. Preferential chemotaxis of activated human CD4+ T cells by extracellular cyclophilin A. J Leukoc Biol 2007; 82: 613-618.
14. Kim H, Kim WJ, Jeon ST, Koh EM, Cha HS, Ahn KS, et al. Cyclophilin A may contribute to the inflammatory processes in rheumatoid arthritis through induction of matrix degrading enzymes and inflammatory cytokines from macrophages. Clin Immunol 2005; 116: 217-224.
15. Satoh K, Nigro P, Matoba T, O'Dell MR, Cui Z, Shi X, et al. Cyclophilin A enhances vascular oxidative stress and the development of angiotensin II-induced aortic aneurysms. Nat Med 2009; 15: 649-656.
16. Weintraub NL. Understanding abdominal aortic aneurysm. N Engl J Med 2009; 361: 1114-1116.
17. Nigro P, Satoh K, O'Dell MR, Soe NN, Cui Z, Mohan A, et al. Cyclophilin A is an inflammatory mediator that promotes atherosclerosis in apolipoprotein E-deficient mice. J Exp Med 2011; 208: 53-66.
18. Shimokawa H, Takeshita A. Rho-kinase is an important therapeutic target in cardiovascular medicine. Arterioscler Thromb Vasc Biol 2005; 25: 1767-1775.
19. Satoh K, Fukumoto Y, Shimokawa H. Rho-kinase: Important new therapeutic target in cardiovascular diseases. Am J Physiol Heart Circ Physiol 2011; 301: H287-H296.
20. Satoh K, Kagaya Y, Nakano M, Ito Y, Ohta J, Tada H, et al. Important role of endogenous erythropoietin system in recruitment of endothelial progenitor cells in hypoxia-induced pulmonary hypertension in mice. Circulation 2006; 113: 1442-1450.
21. Nakayama M, Osaki S, Shimokawa H. Validation of mortality risk stratification models for cardiovascular disease. Am J Cardiol 2011; 108: 391-396.
22. Pencina MJ, D'Agostino RB Sr, D'Agostino RB Jr, Vasan RS. Evaluating the added predictive ability of a new marker: From area under the ROC curve to reclassification and beyond. Stat Med 2008; 27: 157-172; Discussion 207-212.
23. Satoh K, Nigro P, Zeidan A, Soe NN, Jaffre F, Oikawa M, et al. Cyclophilin A promotes cardiac hypertrophy in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol 2011; 31: 1116-1123.
24. Satoh K, Shimokawa H, Berk BC. Cyclophilin A: Promising new target in cardiovascular therapy. Circ J 2010; 74: 2249-2256.
25. Higashi M, Shimokawa H, Hattori T, Hiroki J, Mukai Y, Morikawa K, et al. Long-term inhibition of Rho-kinase suppresses angiotensin IIinduced cardiovascular hypertrophy in rats in vivo: Effect on endothelial NAD(P)H oxidase system. Circ Res 2003; 93: 767-775.
26. Gao JY, Yasuda S, Tsuburaya R, Ito Y, Shiroto T, Hao K, et al. Longterm treatment with eicosapentaenoic acid ameliorates myocardial ischemia-reperfusion injury in pigs in vivo: Involvement of Rhokinase pathway inhibition. Circ J 2011; 75: 1843-1851.
27. Griendling KK, FitzGerald GA. Oxidative stress and cardiovascular injury. Part II: Animal and human studies. Circulation 2003; 108: 2034-2040.
28. Taniyama Y, Griendling KK. Reactive oxygen species in the vasculature: Molecular and cellular mechanisms. Hypertension 2003; 42: 1075-1081.
29. Rao GN, Berk BC. Active oxygen species stimulate vascular smooth muscle cell growth and proto-oncogene expression. Circ Res 1992; 70: 593-599.
30. Baas AS, Berk BC. Differential activation of mitogen-activated protein kinases by H2O2 and O2 in vascular smooth muscle cells. Circ Res 1995; 77: 29-36.
31. Kikuchi Y, Ito K, Ito Y, Shiroto T, Tsuburaya R, Aizawa K, et al. Double-blind and placebo-controlled study of the effectiveness and safety of extracorporeal cardiac shock wave therapy for severe angina pectoris. Circ J 2010; 74: 589-591.
32. Thomas M, Gavrila D, McCormick ML, Miller FJ Jr, Daugherty A, Cassis LA, et al. Deletion of p47phox attenuates angiotensin IIinduced abdominal aortic aneurysm formation in apolipoprotein E-deficient mice. Circulation 2006; 114: 404-413.
33. Seizer P, Schonberger T, Schott M, Lang MR, Langer HF, Bigalke B, et al. EMMPRIN and its ligand cyclophilin A regulate MT1-MMP, MMP-9 and M-CSF during foam cell formation. Atherosclerosis 2010; 209: 51-57.
34. Guo H, Majmudar G, Jensen TC, Biswas C, Toole BP, Gordon MK. Characterization of the gene for human emmprin, a tumor cell surface inducer of matrix metalloproteinases. Gene 1998; 220: 99-108.
35. Haug C, Lenz C, Diaz F, Bachem MG. Oxidized low-density lipoproteins stimulate extracellular matrix metalloproteinase inducer (EMMPRIN) release by coronary smooth muscle cells. Arterioscler Thromb Vasc Biol 2004; 24: 1823-1829.
36. Yurchenko V, Zybarth G, O'Connor M, Dai WW, Franchin G, Hao T, et al. Active site residues of cyclophilin A are crucial for its signaling activity via CD147. J Biol Chem 2002; 277: 22959-22965.